Unlocking the Power of Oncology Data + Specimen Archive for Biomarker and Clinical Discovery and Development

Biomedical research is becoming increasingly data-driven, requiring access to datasets that can drive advancement. In this webinar, learn how our datasets can support product advancement when paired with tissue and molecular samples.

About this webinar

As biomedical research becomes increasingly data-driven, leveraging highly dimensional datasets is crucial for advancing products throughout their life cycles. In particular, access to high-quality imaging and genomic data is essential for driving the success of translational research and test development. This webinar featured industry experts discussing the power of combining biomedical data analysis with matched tissue and molecular samples. Topics included biomarker correlation studies, clinical strategy development, imaging AI model validation, and the potential of longitudinal biomarker research.

Speakers/Facilitators:

Mike Furgason, Ph.D. Head of Data Product, NeoGenomics

Bio: Precision healthcare technologist and Real World Data enthusiast with 15+ years of experience working with healthcare and biomedical data assets(EHR, Genomics, lab, clinical trial data, etc) in both research and product management capacities across industry and academia.

Saumya Pant, Ph.D. VP, Bioinformatics and Data Science, NeoGenomics

Bio: Dr. Saumya Pant is the Vice President of Bioinformatics at NeoGenomics, where she leads a team focused on bioinformatics and data analysis for NGS clinical diagnostics, translational research, and clinical trials. With a Ph.D. in Cell and Molecular Biology from Rutgers, Saumya pioneered circulating nucleic acid liquid biopsy tests during her postdoctoral work at Roche. She is an expert in genomics, NGS, and companion diagnostic development, having led teams at Merck and Bristol Myers Squibb, contributing to key innovations in precision medicine. Before NeoGenomics, she led clinical development at PathAI, supporting drug and diagnostic programs in oncology, metabolic, and immune diseases. Saumya is passionate about transforming patient care through drug R&D, diagnostic development, and data science.

Gustavo Cerqueira, Ph.D. Director/Principal Scientist with Scientific Affairs, NeoGenomics

Bio: Gustavo Cerqueira holds the position of Senior Director at Neogenomics, where he oversees the bioinformatics components related to cancer diagnosis, cancer profiling, and cancer monitoring (MRD, Minimal Residual Disease). He has been responsible for the development and management of Machine Learning models aimed at plasma-based early cancer detection, highly -sensitive identification of cancer biomarkers, and the selection of clinically significant variants within cancer samples.

Kirsteen Maclean, Ph.D. VP, Bioinformatics and Data Science, NeoGenomics

Bio: Kirsteen (Kirsty) Maclean is a Director/Principal Scientist within Scientific Affairs at NeoGenomics with over 20 years of leadership experience addressing academic, clinical, biotechnology, CROs, and pharmaceutical industries through clinical/technical communication, sales support, and market intelligence. Before joining NeoNeoGenomics, Kirsty was the Senior Scientific Director at Ultivue, overseeing digital pathology applications using multiplexed immunofluorescence technology for improved biomarker identification to advance the performance of translational workflows and how we think about clinical trial design in the future.

Previously, Kirsty held leadership roles in commercial development and scientific communications at TelesisBio, Definiens (now part of AstraZeneca), Nanostring, and ThermoFisher Scientific. With over 35 peer-reviewed publications and several book chapters, she holds a PhD in Hematology from University College London, a BS (Hons) in Biochemistry from Glasgow Caledonian University, and extensive academic clinical leadership experience from St. Jude Children’s Research Hospital in Memphis, TN.